Enable Injections Announces $215 Million Financing - 28 January 2022 02:35

CINCINNATI, Jan. 28, 2022 /PRNewswire-AsiaNet/ -- --New financing provides significant financial flexibility to propel growth efforts, benefitting patients, providers, and pharma partners worldwide. Enable Injections, Inc. ( https://enableinjections.com ) ("Enable"), a company developing and m...

  Lifebit partners with NIHR Cambridge Biomedical Research Centr... - 25 January 2022 20:00

LONDON, Jan. 25, 2022 /PRNewswire-AsiaNet/ -- Lifebit today announces a long-term partnership where Lifebit's technology, Lifebit CloudOS, will power a cloud-based Trusted Research Environment (TRE) to serve as the scalable and secure data management and analysis platform for researchers at t...

  IMPRESSION Randomized Trial: Past the halfway mark and progres... - 25 January 2022 02:30

SINGAPORE, Jan. 24, 2022 /PRNewswire-AsiaNet/ -- Concept Medical Inc., [https://www.conceptmedical.com/] focused on vascular intervention drug delivery devices, shares the latest status of its IMPRESSION (sIroliMus coated balloon angioPlasty versus plain balloon angioplasty in the tREatment ...

  Applied Pharmaceutical Science Inc. Announces FDA Approval of ... - 24 January 2022 17:04

BEIJING and PHILADELPHIA, Jan. 24, 2022 /PRNewswire-AsiaNet/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been approve...

  Swiss Pharma Company - IDEOGEN takes over Special Access Progr... - 22 January 2022 03:55

HURDEN, Switzerland, Jan 21, 2022 /PRNewswire-AsiaNet/ -- IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ (R) (belinostat) in Europe, Middle East, North Africa, Russia, and CIS. BELEODAQ (R) is a prescription medicine used to treat patients with a rare form of bloo...

  Hinova Announces First Patient Dosed in a Phase I Clinical Tri... - 21 January 2022 08:30

MELBOURNE, Australia, Jan. 21, 2022 /PRNewswire-Asianet/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, announced that the first patient with metastatic...

  Victor Papamoniodis Joins Medison Pharma as VP International M... - 20 January 2022 23:02

ZUG, Switzerland, Jan 20, 2022 /PRNewswire-AsiaNet/ -- Medison [https://www.medisonpharma.com], a global pharma company focused on providing access to highly innovative therapies to patients in international markets (“Medison”), is proud to announce the joining of Victor Papamoniodis in the newly crea...

  Sputnik V demonstrates strong protection against Omicron varia... - 20 January 2022 22:53

MOSCOW, January 20, 2022, /PRNewswire-AsiaNet/ -- Previous studies also demonstrated additional significant strengthening of protection against Omicron by Sputnik Light booster, which can also be a universal booster to other vaccines to strengthen and lengthen their protection against Omicron. ...

  Successful Completion of First Patient Implantation of MINI WE... - 20 January 2022 19:00

CATANIA, Italy, Jan. 20, 2022 /PRNewswire-AsiaNet/ -- SIFI, a leading international ophthalmic company headquartered in Italy, is pleased to divulge the successful completion of the first patient implantation of MINI WELL(R) and MINI WELL TORIC(R) IOLs in China, announced via Affamed Technologies, Jo...

  Nippon Express (Belgium) Acquires GDP Certification for Facili... - 20 January 2022 18:00

TOKYO, Jan. 20, 2022 /Kyodo JBN-AsiaNet/-- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a company of the Nippon Express Holdings, Inc. Group, has obtained Good Distribution Practice (GDP) certification, effective December 21, 2021, for air and ground forwarding operations...